Autism spectrum disorder represents a range of neurodevelopmental conditions often accompanied by epilepsy or intellectual disability. These disorders manifest through brain alterations established during the earliest stages of development, typically becoming clinically evident in early childhood and persisting throughout life. Despite the immense genetic heterogeneity of ASD, one challenging question has persisted: Do these myriad genetic abnormalities funnel into common biological disruptions during brain development, or do they create unique, gene-specific pathologies?

To unravel this, Novarino and her collaborators embarked on an ambitious endeavor. They undertook a comprehensive analysis across diverse genetic models of ASD, focusing on high-risk genes that have been strongly implicated in the disorder. Their aim was to identify whether the molecular cascades impacted by distinct mutations converge on shared cellular pathways or diverge into discrete, mutation-specific signatures. This question required an unprecedented scale of molecular data collection and integration.

Technological advances in multi-omics sequencing have made it possible to generate such detailed datasets. The team harnessed “single-nucleus multi-omics sequencing,” a sophisticated technique that permits simultaneous interrogation of multiple layers of nuclear information from individual cells. This method encompasses not only genomic sequences but also transcriptomic profiles—reflecting which genes are actively expressed—and epigenomic modifications that regulate gene activity without altering the underlying DNA code. This multi-dimensional approach enables researchers to dissect the intricate regulatory architecture within each nucleus with unprecedented resolution.

By examining over 250 samples derived from two functionally distinct brain regions in both male and female mice at various developmental stages, the research team achieved a panoramic view of neurodevelopmental changes prompted by ASD-linked mutations. Their data revealed a remarkable convergence: different genetic mutations ultimately affected overlapping cortical cell types and molecular processes during critical windows of brain maturation. These shared perturbations centered on transient delays in neuronal differentiation and synaptic connectivity, rather than permanent cellular defects.

Intriguingly, the study also illuminated sex-specific responses to ASD-associated genetic changes. Female mice exhibited distinct molecular and activity-dependent alterations compared to males, suggesting that biological sex modulates the trajectory of ASD pathophysiology. Such findings underscore the necessity for precision medicine paradigms that account for sex as a fundamental biological variable in autism intervention strategies.

Although the mutations induced shared effects on brain development, each genetic model bore unique molecular fingerprints, highlighting the heterogeneity beneath the surface convergence. This duality—common developmental disruptions intersecting with mutation-specific signatures—illustrates the complexity researchers face when designing therapeutic approaches for ASD. Not all interventions will be universally effective; instead, treatments must be contextualized within an individual’s genetic background, biological sex, and stage of neurodevelopment.

The transient nature of many observed abnormalities is particularly noteworthy. The molecular delays in neural maturation and connectivity, which diminish approximately two weeks postnatally in mouse models, hint at critical windows for therapeutic intervention. Early-stage modulation of these developmental pathways might correct or compensate for aberrant trajectories before they solidify into chronic dysfunction. This temporal aspect suggests that the timing of treatment administration is as critical as its molecular target.

Furthermore, the integration of molecular and physiological data revealed that alterations in brain activity paralleled the molecular signatures, providing functional validation of the observed molecular perturbations. This linkage between genotype, molecular phenotype, and electrophysiological effect forms a robust platform for future studies targeting neural circuit function in ASD.

The implications of this work extend beyond the confines of autism research. It enhances the broader understanding of human cortical development, shedding light on how diverse genetic insults can disrupt the delicate choreography of neurogenesis and circuit assembly. The study exemplifies the power of combining advanced sequencing technologies with rigorous developmental neuroscience to decode the complexity of brain disorders.

Moving forward, the Novarino group advocates for therapeutic strategies that are tailored not only to specific genetic causes but also to the developmental timing and sex of the individual. This multidimensional approach challenges the conventional one-size-fits-all paradigm and promotes personalized medicine founded on a precise understanding of the biological landscape unique to each patient’s autism.

Autism affects millions worldwide, impacting families across every culture and community. The insights from this seminal study represent a significant leap toward demystifying ASD’s biological roots. By revealing the nuances of brain development altered by different mutations, the research brings the field closer to developing timely, targeted interventions that can improve the quality of life for affected individuals.

The continued integration of single-cell multi-omics and functional neuroscience promises to yield deeper insights into the dynamic processes that sculpt the developing brain. By harnessing these cutting-edge tools, researchers can chart the complex interplay of genetic and epigenetic factors that culminate in ASD, ultimately driving innovative solutions for diagnosis and therapy.

In sum, this research exemplifies how modern molecular tools can unravel the layered complexity of neurodevelopmental disorders. It marks a critical step toward understanding autism not as a monolithic condition but as a constellation of biological phenomena intertwined through common developmental pathways and individualized molecular signatures. As the scientific community takes up the challenge of translating these findings into clinical applications, the future holds promise for more effective, personalized approaches to autism care that embrace the disorder’s inherent diversity.

Subject of Research: The molecular and cellular mechanisms underpinning autism spectrum disorder using mouse models to study cortical development dynamics.

Article Title: Cortical development dynamics across autism spectrum disorder mouse models.

News Publication Date: 17 June 2026

Web References:
DOI: 10.1038/s41586-026-10679-1

Image Credits: © Mohammad Goudarzi / ISTA

Keywords

Autism, Autism Spectrum Disorder, ASD, Neurodevelopmental Disorders, Cortical Development, Single-Nucleus Sequencing, Multi-Omics, Epigenetics, Genetics, Mouse Models, Neuroscience, Brain Development, Neurogenetics, Developmental Neuroscience

The investigation leverages a rich array of birth cohorts, genome-wide association studies (GWAS), and polygenic risk scoring techniques to dissect the genetic underpinnings related to age at autism diagnosis. Notably, the authors quantify SNP-based heritability for age at diagnosis at approximately 11%, indicating meaningful but incomplete genetic influence. Crucially, the genetic correlation between earlier- and later-diagnosed autism is moderate, confirming that these are not simply different phenotypic expressions of a single genetic entity but rather reflect at least two partly independent polygenic latent factors influencing developmental outcomes.

Furthermore, the study integrates longitudinal behavioral data from multiple population samples, tracing socioemotional and neurodevelopmental trajectories with the Strengths and Difficulties Questionnaire (SDQ). The polygenic scores for early- versus late-diagnosed autism diverge markedly in their relationship to changes in SDQ total difficulties scores, reinforcing the premise that these two autism variants follow different developmental courses. This developmental-genetic dissonance underscores that age at diagnosis does not merely reflect diagnostic practice or environmental variables but points robustly toward differing underlying biology.

The implications of this research extend beyond autism itself to broaden our concept of neurodevelopmental disorders and their interplay with mental health. Later-diagnosed autism shows stronger genetic correlation with attention deficit hyperactivity disorder (ADHD)—a link weak or absent in earlier diagnosis profiles—and this variation is congruent with the temporal emergence of related neuropsychiatric symptoms. Within-family genetic transmission analyses further corroborate these findings by demonstrating preferential over-transmission of ADHD risk alleles among individuals diagnosed later with autism, illuminating a window into complex pleiotropic genetic mechanisms.

Adding another dimension to these findings, the study reveals that the polygenic risk factor for later-diagnosed autism aligns with elevated mental-health difficulties such as anxiety and depression. This evidence lends genetic-based credence to epidemiological observations that individuals receiving autism diagnoses later in life often confront greater co-occurring psychiatric challenges. This intersection of genetic and clinical traits importantly calls for precision in interpreting sex and gender differences within autism since females typically receive later diagnoses, suggesting that previously reported sex disparities may partly result from age-related diagnostic biases rather than purely biological distinctions.

However, the authors carefully delineate the study’s limitations, notably the modest proportion of variance explained by common genetic variation, which points to myriad environmental, cultural, and potentially unmeasured biological contributors influencing age at diagnosis. Additionally, reliance on parent-reported SDQ scores limits capturing the full spectrum of core autistic traits, and the exclusive focus on European ancestries curtails the generalizability across global populations. The researchers emphasize the need to pursue more comprehensive, diverse longitudinal cohorts and genetically stratified designs to deepen the mechanistic understanding.

Despite these constraints, the study’s demonstration of a two-latent-trait polygenic model disrupts conventional autism genomics paradigms. It resolves prior inconsistencies in genetic correlations observed across GWAS datasets by contextualizing differences within age-at-diagnosis strata. Notably, combining data from various cohorts with differing diagnosis ages explains why some autism GWAS show stronger overlaps with ADHD and why others do not, clarifying a long-standing conundrum in psychiatric genetics.

This reconceptualization carries profound implications for clinical practice as well. Recognizing early- and late-diagnosed autism as genetically and developmentally heterogeneous could refine diagnostic criteria and guide tailored interventions. It suggests that early identification efforts might benefit from distinct biomarkers and therapeutic strategies compared to cases diagnosed in adolescence or adulthood. Moreover, disentangling genetic confounding associated with age at diagnosis can enhance the accuracy of research into sex and gender differences, co-occurring mental health conditions, and longitudinal outcomes.

Looking forward, this paradigm invites a reexamination of how neurodevelopmental trajectories are studied, urging a shift toward models that accommodate continuous gradients rather than discrete categories. It encourages integrating genetic profiles with lifetime phenotypic evolution, expanding beyond static diagnostic labels to embrace developmental complexity. Such approaches may illuminate hidden subtypes within autism and other neuropsychiatric disorders, yielding precision medicine strategies aligned with individual genomic and phenotypic landscapes.

In sum, Zhang et al.’s study represents a pivotal advance that refines the genetic architecture of autism, emphasizing that age at diagnosis is a critical axis of heterogeneity with meaningful biological, clinical, and mental health correlates. This nuanced genetic insight not only elucidates why the autism spectrum is so phenotypically diverse but also charts a course for future research to unravel the intricate developmental paths shaping this multifaceted condition. By bridging genomics, developmental epidemiology, and psychiatric phenotyping, it redefines how the scientific and medical communities conceptualize and approach autism.

Subject of Research: Genetic and developmental heterogeneity in autism spectrum disorder as influenced by age at diagnosis.

Article Title: Polygenic and developmental profiles of autism differ by age at diagnosis.

Article References:
Zhang, X., Grove, J., Gu, Y. et al. Polygenic and developmental profiles of autism differ by age at diagnosis. Nature (2025). https://doi.org/10.1038/s41586-025-09542-6

Image Credits: AI Generated